Dr. Andreea Coca, MD
Rheumatology (Rheumatology Physician)
- Medicare participating
At a glance
- Years since graduation
- 33
- In the NPI registry since
- 2007
- Medicare patients seen, 2024
- 105
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2007Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Rheumatology Physician primary
NY license 2535481
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- UPMC Presbyterian Shadyside Pittsburgh, PA
- Magee Womens Hospital of UPMC Health System Pittsburgh, PA
- UPMC PAssavant Pittsburgh, PA
- UPMC Altoona Altoona, PA
- UPMC Mercy Pittsburgh, PA
Medical groups
- University of Pittsburgh Physicians (4,236 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 105
- Services billed
- 270
- Patients’ average age
- 67
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 30-39 minutes | 42 | 33 |
| New patient office or other outpatient visit, 45-59 minutes | 12 | 12 |
| New patient office or other outpatient visit, 60-74 minutes | 11 | 11 |
| Established patient office or other outpatient visit, 40-54 minutes | 11 | 11 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Hydroxychloroquine Sulfate Other prescribers in Pittsburgh, PA | 343 |
| Methotrexate (methotrexate sodium) Other prescribers in Pittsburgh, PA | 185 |
| Prednisone Other prescribers in Pittsburgh, PA | 142 |
| Mycophenolate Mofetil Other prescribers in Pittsburgh, PA | 72 |
| Leflunomide Other prescribers in Pittsburgh, PA | 50 |
| Humira(Cf) Pen (adalimumab) Other prescribers in Pittsburgh, PA | 45 |
| Enbrel Sureclick (etanercept) Other prescribers in Pittsburgh, PA | 41 |
| Benlysta (belimumab) | 41 |
| Alendronate Sodium Other prescribers in Pittsburgh, PA | 36 |
| Cevimeline Hcl | 35 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Industry-funded research
Named as a principal investigator on 5 industry-funded studies in 2025, from 3 companies. The companies reported $125,986 in research payments for these studies, mostly to the institutions running them.
- A Randomized, Double-blind, Parallel Group, Placebo-controlled Multicenter Phase 3 Study to Evaluate Efficacy, Safety and Tolerability of Two Regimens of Ianalumab on Top of Standard-of-care Therapy in Patients With S…
Novartis Pharmaceuticals Corporation - A Study to Evaluate the Efficacy and Safety of Dapirolizumab Pegol in Study Participants With Moderately to Severely Active Systemic Lupus Erythematosus
UCB SA · Recruiting · NCT06617325 - Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus
AbbVie Inc. · Active, not recruiting · NCT05843643 - A Study to Evaluate the Efficacy and Safety of Dapirolizumab Pegol in Study Participants With Moderately to Severely Active Systemic Lupus Erythematosus
UCB SA · Completed · NCT04294667 - Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE)
AbbVie Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.